psi-697

PSI-697 is a small molecule quinoline derivative developed as an oral antagonist of P-selectin. It was investigated for its potential to treat vascular and thrombotic diseases by inhibiting the interaction between P-selectin and its ligand (P-selectin glycoprotein ligand-1), thereby reducing leukocyte and platelet adhesion and rolling—key processes in inflammation and thrombosis. Preclinical studies demonstrated that PSI-697 could reduce leukocyte rolling in inflamed vessels and decrease thrombus formation in animal models without increasing bleeding risk. However, clinical trials showed that PSI-697 did not significantly inhibit platelet–monocyte aggregate formation in humans at tested doses. The drug reached Phase 1 clinical trials for scleritis but development has since been discontinued[1][3][4][5][6][7].

Other names

2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acidP-selectin inhibitor851546-61-7UNII-LH1XC916MEUNII-LH-1XC916MEUNII-LH 1XC916ME